Nuestros recursos

NEW YORK – June 7, 2021 – ObvioHealth, a global virtual research organization (VRO), is bringing clinical trial data fully into the continuum of care through a new strategic partnership with Dedalus Group, the leading healthcare and diagnostic software solutions provider in Europe.

ObvioHealth is excited to announce the completion of enrollment for its latest completely virtual research study. Our digital, disruption-free, approach to recruitment allowed participants to enroll from the safety of their homes.

ObvioHealth will integrate Hyfe's technology into its decentralized clinical trials platform and smartphone app to capture and analyze coughing events.

ObvioHealth, a global Virtual Research Organization (VRO), announces its next generation platform offering enhanced remote patient monitoring capabilities for the company’s end-to-end decentralized clinical trial solutions.

ObvioHealth, a global Virtual Research Organization(VRO), announces it has raised $31 million in its latest round of financing. The round was led by two new partners: Dedalus Group, an international healthcare IT and diagnostic software provider, leader in Europe and backed by Ardian, and Novotech Health Holdings Pte. Ltd.(“Novotech”), Asia Pacific’s highest revenue biotech-specialistCRO in 2020.

Despite the industry efforts to refine the processfor remote patient monitoring and outcomes measurement, accurate, complete real-worlddata is tough to capture. Our presentation offers insider industry knowledgegained from DCTs that employed next-gen ePRO and audio/image capture technologyto deliver reliable data sets.

At MAGI 2020, we spoke on the many advantages of 'going virtual.' Our presentation revolves around one critical observation: not every trial can go virtual, but every trial can benefit from implementing virtual elements. Virtual clinical trials make for happier, engaged patients who produce better data. Our patient-centric DCTs are evidence.